Clinical Trial Update: Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for identifying biomarkers of response to aflibercept (Zaltrap) in metastatic colorectal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Zaltrap (ramucirumab)

Snippet

Sponsor: CR-CSSS Champlain-Charles-Le Moyne | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: TERMINATED